Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Brca2 and trp53 deficient mouse tumours

ABSTRACT: Whole-exome DNA sequence analysis of Brca2 and Trp53 deficient mouse mammary gland tumours

PROVIDER: PRJEB6674 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR557068_1.fastq.gz	Fastqsanger.gz
	ERR557068_2.fastq.gz	Fastqsanger.gz
	ERR557069_1.fastq.gz	Fastqsanger.gz
	ERR557069_2.fastq.gz	Fastqsanger.gz
	ERR557070_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Gene expression - GLI1 induced mammary gland tumours

Project description:Increased expression of GLI1 is associated with poor prognosis for some breast cancer subtypes. A conditional transgenic GLI1 expressing mouse model, with or without heterozygous deletion of Trp53, was used to generate and study GLI1 induced mammary gland tumours. Tumour tissue was serially orthotopically transplanted for at least 10 generations in NSG mice.

2019-06-30 | E-MTAB-7531 | biostudies-arrayexpress

RNA-seq profiling of mammary epithelial cell populations from Brca2 knockout and wildtype mice

Project description:Brca2(fl/fl)Trp53(fl/fl) mice were crossed with MMTV-cre mice to create mice with both alleles of Brca2 and one allele of Trp53 deleted (refered to as Brca2KO). Mature luminal, luminal progenitor and basal mammary epithelial cell populations were sorted from Brca2KO and wildtype mice. Transcriptional profiling revealed marked perturbation within the luminal Brca2KO compartment

2023-12-06 | GSE232631 | GEO

NRF2 activation in TRP53:P16 deficient mice drives oral squamous cell carcinoma

Project description:NRF2 activation in TRP53:P16 deficient mice drives oral squamous cell carcinoma

2024-01-31 | PXD048887 | Pride

MiDAS in BRCA2-deficient cells originate at early S-phase transcription-replication conflicts

Project description:Multiple replication abnormalities cause cells lacking BRCA2 to enter mitosis with under-replicated DNA and to activate mitotic DNA synthesis (MiDAS). However, the precise position of these MiDAS sites, as well as their origin, remains unknown. Here we labelled mitotic nascent DNA and performed high-throughput sequencing to identify at high-resolution the sites where MiDAS occurs in the absence of BRCA2. This approach revealed 150 genomic loci affected by MiDAS, which map within regions replicating during early S-phase and are therefore distinct from the aphidicolin-induced common fragile sites. Moreover, these sites largely localise near early firing origins and within genes transcribed in early S, suggesting that they stem from transcription-replication conflicts (TCRs). Inhibiting transcription with 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) during early S-phase abrogates MiDAS. Strikingly, MiDAS sites co-localise with genomic loci where R-loops form in unchallenged conditions, suggesting that R-loop accumulation caused by BRCA2 inactivation leads to DNA lesion which are repaired by MiDAS. RAD52 is required in this process, as its abrogation in BRCA2-deficient cells reduces the rate of MiDAS and causes DNA damage accumulation in G1. Furthermore, MiDAS sites triggered by BRCA2 inactivation are hotspots for genomic rearrangement in BRCA2-mutated breast tumours. These results indicate that BRCA2 acts in early S-phase to protect TRC- and R-loop-induced DNA lesions, thereby preventing them from becoming a source of genomic instability and tumorigenesis.

2022-08-01 | GSE196163 | GEO

Copy Number Variation in Brca2 (G25R) variant mouse tumors

Project description:To understand the overall amount of genomic instability seen in various genotypes of Brca2 (G25R) and to see where common gains and losses occur within a Trp53 heterozygous genetic background Comparing mouse tumor DNA with mouse genomic DNA

2016-07-27 | E-GEOD-84854 | biostudies-arrayexpress

Copy Number Variation in Brca2 (G25R) variant mouse tumors

2016-07-27 | GSE84854 | GEO

Expression data from Trp53- or Atm-deficient Eµ-TCL1 murine CLL cells

Project description:To analyze expression differences between Trp53 pro-and deficient as well as Atm pro- and deficient murine CLL tumors developing in the Eµ-TCL1 mouse model, we analyzed splenocytes isolated from heavily infiltrated spleens of sick mice. To investigate differences in the response to cyclophosphamide, we also analyzed splenocytes from leukemic animals that were isolated twelve hours after intraperitoneal injection of cyclophosphamide.

2017-05-16 | GSE98904 | GEO

SDH deficient renal tumours RNA

Project description:Succinate dehydrogenase (SDH) deficient renal cancers are a rare and understudied subtype of renal cancer. As such they represent an unmet need in kidney cancer research. Here, we seek to describe the genomics and transcriptomics of SDH deficient renal cancers by sequencing five such tumours.

| EGAS00001004103 | EGA

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories

Project description:Germline mutations in the BRCA2 tumour suppressor are associated with both an increased lifetime risk of developing prostate cancer (PCa) and increased risk of aggressive disease. To understand this aggression, here we profile the genomes and methylomes of localized PCa from 14 carriers of deleterious germline BRCA2 mutations (BRCA2-mutant PCa). We show that BRCA2-mutant PCa harbour increased genomic instability and a mutational profile that more closely resembles metastastic than localized disease. BRCA2-mutant PCa shows genomic and epigenomic dysregulation of the MED12L/MED12 axis, which is frequently dysregulated in metastatic castration-resistant prostate cancer (mCRPC). This dysregulation is enriched in BRCA2-mutant PCa harbouring intraductal carcinoma (IDC). Microdissection and sequencing of IDC and juxtaposed adjacent non-IDC invasive carcinoma in 10 patients demonstrates a common ancestor to both histopathologies. Overall we show that localized castration-sensitive BRCA2-mutant tumours are uniquely aggressive, due to de novo aberration in genes usually associated with metastatic disease, justifying aggressive initial treatment.

2017-01-10 | GSE80685 | GEO

BET inhibition induces synthetic lethality in BRCA2-deficient pancreatic cancer via autophagy-dependent cell death [RNA-Seq]

Project description:To model familial pancreatic cancer patients, we generated isogenic Brca2 deficient pancreatic cancer cell lines with CRISPR/Cas9. To investigate the changes in the transcriptome profiles upon BET inhibition, we performed RNA-seq.

2023-09-21 | GSE207295 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data